# Rivaroxaban Hypericum Trial

> **NCT03796377** · PHASE1 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 12 (actual)

## Conditions studied

- Drug Interaction Study

## Interventions

- **DRUG:** St Johns Wort Extract
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT03796377
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-13
- **Primary completion:** 2019-04-09
- **Final completion:** 2019-04-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03796377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03796377, "Rivaroxaban Hypericum Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03796377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*